David A. Siegel Cue Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.11 - $4.91 $18,660 - $29,460	-6,000 Reduced 18.13%	27,100 $98,000
Q1 2023 May 15, 2023	SELL	$2.41 - $3.74 $182,678 - $283,492	-75,800 Reduced 69.61%	33,100 $118,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $177,816 - $293,880	-74,400 Reduced 40.59%	108,900 $310,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $68,684 - $103,796	-30,800 Reduced 14.39%	183,300 $409,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $21,414 - $50,912	8,600 Added 4.18%	214,100 $533,000
Q1 2022 May 16, 2022	SELL	$4.41 - $12.28 $95,697 - $266,476	-21,700 Reduced 9.55%	205,500 $1 Million
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $273,672 - $449,820	25,200 Added 12.48%	227,200 $2.57 Million
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $965,760 - $1.47 Million	-96,000 Reduced 32.21%	202,000 $2.94 Million
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $742,290 - $989,493	-68,100 Reduced 18.6%	298,000 $3.47 Million
Q1 2021 May 17, 2021	BUY	$11.2 - $16.09 $172,480 - $247,786	15,400 Added 4.39%	366,100 $4.47 Million
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $637,176 - $939,719	57,300 Added 19.53%	350,700 $4.39 Million
Q3 2020 Nov 16, 2020	BUY	$15.05 - $23.54 $2.34 Million - $3.67 Million	155,800 Added 113.23%	293,400 $4.42 Million
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $1.61 Million - $3.9 Million	127,000 Added 1198.11%	137,600 $3.37 Million
Q1 2020 May 15, 2020	BUY	$9.85 - $22.27 $104,410 - $236,062	10,600 New	10,600 $150,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.